Navigation Links
Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Date:2/8/2010

HAYWARD, Calif., Feb. 8 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome. This pivotal study, which is expected to begin in the first half of this year and to be completed 18 months thereafter, is expected to enroll up to 6,500 patients. Patients will be randomized within 96 hours of an acute coronary syndrome and will receive 16 weeks of either once-daily of A-002 or placebo in addition to a dose of atorvastatin.

In addition, Anthera today announced that it has appointed Daniel K. Spiegelman to its Board of Directors and as Chairman of the Audit Committee of the Board of Directors.  Mr. Spiegelman provides management and financial consulting services to biotechnology companies. From 1998 to 2009, Mr. Spiegelman served as Senior Vice President and Chief Financial Officer of CV Therapeutics, Inc., a biopharmaceutical company that was acquired by Gilead Sciences, Inc. in 2009. From 1991 to 1998, Mr. Spiegelman served at Genentech, Inc., most recently as Treasurer. Mr. Spiegelman also serves on the board of directors of Affymax, Inc., Cyclacel Pharmaceuticals, Inc., Omeros Corporation and Oncothyreon, Inc., all publicly traded biopharmaceutical companies. Mr. Spiegelman holds a B.A. in economics from Stanford University and
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
2. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
3. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
4. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
5. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
7. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
8. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
9. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
10. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
11. Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 The global ... basis of sectors, products & services and application. And ... with the increasing demand of advanced drugs for ... propel the growth for bioinformatics market. The implementation ... is known as bioinformatics. Decreasing cost of DNA ...
(Date:9/1/2015)... DUBLIN , Aug. 31, 2015 ... the addition of the "Introduction to Veterinary ... to their offering. This course ... a good introduction to those concerned with Veterinary ... experienced personnel who reqire a better understanding of ...
(Date:9/1/2015)... , Sept. 1, 2015  Abbott (NYSE: ABT ... a multi-center, randomized trial comparing the safety and effectiveness ... ® , Abbott,s market-leading, permanent drug eluting stent. ... Japan and enrolled 400 people with ... disease. The results will be featured at a late-breaking ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Introduction to Veterinary Pharmacovigilance Seminar (London, UK - September 23-24) 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4
... has released an updated AutoLabel solution with enhanced customized ... virtually 100% of medications have a scan-ready bar code ... AutoLabel is a complete barcoding solution that provides color-coded ... improve patient safety at the bedside. New features include ...
... ("CTI") (NASDAQ and MTA: CTIC) announced that final results ... relapsed or refractory acute myeloid leukemia ("AML") was selected ... of Hematology ("ASH") Annual Meeting, which will be held ... Jorge Cortes, M.D., of The University of ...
Cached Medicine Technology:Talyst Updates Its AutoLabel® Solution 2Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting 2Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting 3Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting 4
(Date:9/1/2015)... York (PRWEB) , ... September 01, 2015 , ... Zecurion, ... Zlock Mac , its groundbreaking new version of endpoint DLP developed specifically for Mac ... Mac, in which more than 100 IT and information security professionals had participated. The ...
(Date:9/1/2015)... ... September 01, 2015 , ... Two of Washington D.C.’s most respected chefs ... and dining. , Recently named “the next big thing” in the culinary world ... telling the whole story behind food and reclaiming culinary traditions on the brink of ...
(Date:9/1/2015)... ... 2015 , ... METTLER TOLEDO has announced an upcoming webinar ... , featuring Ed Szczesny (Quality Assurance, Rhodes Pharmaceuticals) as guest presenter. This webinar ... , Calibration, qualification, and the appropriate level of routine testing for laboratory instruments ...
(Date:9/1/2015)... ... , ... Mercy Health (formerly Catholic Health Partners) – a Catholic healthcare ministry ... Helping You Be Well videos to prostate cancer awareness. Prostate cancer is the most-common, ... video on Mercy Health’s YouTube channel, Mercy Health experts address issues, such as:, ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... 9, 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis Downtown, 350 ... with career opportunities will be attending from across the country. All specialties will ...
Breaking Medicine News(10 mins):Health News:Zecurion Announces Endpoint Security for Mac 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4
... brain responsible for imitation may be behind the unique ... searching for roots of empathy have now found brain ... also identified a network of brain regions that are ... enable a person to distinguish the self from others.The ...
... conduct tests for any Indian doctor having graduated abroad avid ... higher standards amongst doctors, the government has made it compulsory ... today. , The new regulations, ... students who want to enrol in MBBS course abroad will ...
... Four people are confirmed dead from pneumonic plague in ... plague from a remote village of Himachal Pradesh state ... // ,"The sequence of tests collectively confirmed that ... known as pneumonic plague," Federal Health Minister C.P. Thakur ...
... many people trying to lose weight are not using the right ... cent of men and 50 per cent of women said ... to lose weight or at least not gain any more. ... and one fourth of those keeping their weight stable were using ...
... By the use of novel scanning methods doctors have found that ... brain. It is the section that governs the body clock, which ... ,Cluster headaches are marked by a sudden tormenting pain on one ... can last for 20 minutes to 3 hours. Affecting 0.1% of ...
... and vitamins increased the exercise capacity and quality of life ... can produce the gas nitric oxide which, in turn, may ... that arginine might help people with heart problems, especially those ... ,In fact the validation for arginine supplements so far ...
Cached Medicine News:Health News:The brain wave 2
... ergonomic chairs with concave seats ... support • Select options like ... and glides. • BTT/1P chairs ... environments: industry, education, laboratory, clean ...
... with concave seats and standard-sized ... Select options like seats, backrests, ... • BTT/1P chairs are recommended ... education, laboratory, clean room, static ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
Medicine Products: